# ASHP CLINICAL SKILLS COMPETITION PHARMACIST'S PATIENT DATA BASE FORM

Demographic and Administrative Information				
Name: Rogers, Buckley	Patient ID: 110606			
Address: 12 45 <sup>th</sup> Street	Room & Bed: Neurology ICU Room 221			
Ocean City, NJ	Physician: Rose			
Date of Birth: 4-5-1938	Pharmacy: CVS #34234524			
Height: 71" Weight: 110 kg	Race: Caucasian			
Gender: Male	Religion: None specified			
History of Present Illness	Vitals & Other Tests			
BR presented to the ED 7days ago with mental status changes after a fall. EEG showed that he had a grand mal seizure. He was emergently intubated for airway protection and placed on a ventilator. A chest X-ray was performed to confirm endotracheal tube placement and did not have signs of pneumonia. He was transferred to the Neurology ICU and diagnosed with a subarachnoid hemorrhage (SAH).  Yesterday (hospital day #6) BR's nurse noted that he had thick, copious secretions. Today (hospital day #7) BR spiked a fever to 102.3° F and has new leukocytosis. A chest X-ray reveals an infiltrate in the left lower lobe, and the team diagnoses him with pneumonia. His blood pressure drops precipitously and does not respond to fluid resuscitation with 4L of normal saline and he was started on norepinephrine at 4 mcg/min.	BP 84/44 Pulse 120 Temp Tmax 102.3			
Past Medical History	Chemistry and CBC			
CAD s/p MI 2004	HD#1 HD #6 HD#7   Na 140 Na 140 Na 140			
Hypertension	K 3.9 K 4.2 K 4.2			
Hyperlipidemia				
Chronic Renal Insufficiency	C    100   C    100   C    100			
	Cl 100 Cl 100 Cl 100 CO <sub>2</sub> 21 CO <sub>2</sub> 24 CO <sub>2</sub> 24			
	$\begin{array}{ c c c c c c c c c c c c c c c c c c c$			
DVT 2 months ago	CO2         21         CO2         24         CO2         24           BUN         27         BUN         42         BUN         45			
	$\begin{array}{ c c c c c c c c c c c c c c c c c c c$			
DVT 2 months ago	CO2     21     CO2     24     CO2     24       BUN     27     BUN     42     BUN     45       SCr     1.5     SCr     2.3     SCr     2.6			
DVT 2 months ago	CO <sub>2</sub> 21 CO <sub>2</sub> 24 CO <sub>2</sub> 24 BUN 45 SCr 1.5 SCr 2.3 SCr 2.6 Glucose 168 Glucose 172 Glucose 194  WBC 7.8 WBC 14.5 WBC 18.9 Hgb 11.4 Hgb 11.5 Hgb 10.9 HCT 34.2 HCT 33.4 HCT 32.1 Plts 286 Plts 186 Plts 168  Calcium 9.2			
DVT 2 months ago	CO2       21       CO2       24       CO2       24         BUN       27       BUN       42       BUN       45         SCr       1.5       SCr       2.3       SCr       2.6         Glucose       168       Glucose       172       Glucose       194         WBC       7.8       WBC       14.5       WBC       18.9         Hgb       11.4       Hgb       11.5       Hgb       10.9         HCT       34.2       HCT       33.4       HCT       32.1         Plts       286       Plts       186       Plts       168			
DVT 2 months ago	CO2       21       CO2       24       CO2       24         BUN       27       BUN       42       BUN       45         SCr       1.5       SCr       2.3       SCr       2.6         Glucose       168       Glucose       172       Glucose       194         WBC       7.8       WBC       14.5       WBC       18.9         Hgb       11.4       Hgb       11.5       Hgb       10.9         HCT       34.2       HCT       33.4       HCT       32.1         Plts       286       Plts       186       Plts       168         Calcium       9.2       Albumin       2.8       Lactate       7.2			
DVT 2 months ago	CO2       21       CO2       24       CO2       24         BUN       27       BUN       42       BUN       45         SCr       1.5       SCr       2.3       SCr       2.6         Glucose       168       Glucose       172       Glucose       194         WBC       7.8       WBC       14.5       WBC       18.9         Hgb       11.4       Hgb       11.5       Hgb       10.9         HCT       34.2       HCT       33.4       HCT       32.1         Plts       286       Plts       186       Plts       168         Calcium       9.2       Albumin       2.8       Lactate       7.2         AST       34       AST       34       AST       54			
DVT 2 months ago	CO2       21       CO2       24       CO2       24         BUN       27       BUN       42       BUN       45         SCr       1.5       SCr       2.3       SCr       2.6         Glucose       168       Glucose       172       Glucose       194         WBC       7.8       WBC       14.5       WBC       18.9         Hgb       11.4       Hgb       11.5       Hgb       10.9         HCT       34.2       HCT       33.4       HCT       32.1         Plts       286       Plts       186       Plts       168         Calcium       9.2       Albumin       2.8       Lactate       7.2			
DVT 2 months ago Depression	CO2         21         CO2         24         CO2         24           BUN         27         BUN         42         BUN         45           SCr         1.5         SCr         2.3         SCr         2.6           Glucose         168         Glucose         172         Glucose         194           WBC         7.8         WBC         14.5         WBC         18.9           Hgb         11.4         Hgb         11.5         Hgb         10.9           HCT         34.2         HCT         33.4         HCT         32.1           Plts         286         Plts         186         Plts         168           Calcium         9.2         Albumin         2.8         Lactate         7.2           AST         34         AST         34         AST         54           ALT         37         ALT         41         Total bili         1.1           Direct bili         0.6         Direct bili         0.6         Direct bili         0.6			
DVT 2 months ago	CO2         21         CO2         24         CO2         24           BUN         27         BUN         42         BUN         45           SCr         1.5         SCr         2.3         SCr         2.6           Glucose         168         Glucose         172         Glucose         194           WBC         7.8         WBC         14.5         WBC         18.9           Hgb         11.4         Hgb         11.5         Hgb         10.9           HCT         34.2         HCT         33.4         HCT         32.1           Plts         286         Plts         186         Plts         168           Calcium         9.2         Albumin         2.8         Lactate         7.2           AST         34         AST         34         AST         54           ALT         37         ALT         41         Total bili         1.1           Direct bili         0.6         Direct bili         0.6         Direct bili         0.6			

# ASHP CLINICAL SKILLS COMPETITION PHARMACIST'S PATIENT DATA BASE FORM (Cont.)

Social History (from outpatient chart)	Cultures				
Tobacco: Denies	HD #1				
ETOH: Occasional	Blood culture 2/2 no growth				
Illicit Drugs: Past history of occasional marijuana, last used >20	Urine culture - <10,000 GNRs				
years ago	Urinalysis (from HD #1)				
Caffeine: Occasional	Appearance – Clear, yellow				
Occupation: Retired Astronaut	Specific gravity – 1.017				
Status: Widowed	Blood – Trace				
<u>Children</u> : None	Ketones – Trace				
Physical Activity: Moderate	Leukocyte esterase – Trace				
<u>Diet</u> : Nothing notable	Nitrites – Negative				
	Protein 4+				
	Glucose – Trace				
	Yeast 2+				
	WBCs – 0-4 per high powered field				
	RBCs – 4-10 per high powered field				
Procedures	X-ray				
Intubated and placed on ventilator upon admission	Chest (Day #7) – Left lower lobe consolidation				
Externalized ventricular drain (ventriculostomy) placed on hospital	Radiologist interpretation: probable				
day #1	pneumonia				
EEG on day 1 showed seizure activity that has resolved					
Nasogastric tube placed for tube feeds and medications					
An IVC filter was placed on day #5.					
Lower extremity Doppler – negative for DVT in both LEs					
Physical Exam					
General – Elderly, obese man who is sedated on a ventilator					
Skin – Cool extremities with 2+ edema in lower extremities					
HEENT – PERRLA; pink conjuctiva					
Chest – decreased breath sounds and crackles on left side					
CV – tachycardic, +S1S2, no bruits					
Abd – Soft, non-distended; no masses or obvious tenderness					
Neuro – Limited by sedation; deep tendon reflexes normal; tested cranial nerves normal					

## ASHP CLINICAL SKILLS COMPETITION PHARMACIST'S PATIENT DATA BASE FORM (Cont.)

Allergies/Intolerance's		Prescription Coverage		
Penicillin - Rash		Insurance: Medicare		
		Copay:		
		Cost per month:		
		Annual Income:		
<b>Current Drug Therapy</b>				
Drug Name/Dose/Strength/Route	Prescribed Schedule	Duration Start-Stop Dates	Indication	
1. Propofol infusion at 20 mcg//kg/min	Continuous infusion	HD #1 – present	Sedation	
2. Sliding scale insulin	PRN after glucose checks	HD #1 – present	Hyperglycemia	
3. Simvastatin 20 mg via tube	Daily	HD #1 – present	Hyperlipidemia	
4. Lansoprazole Solutab 30mg	Daily	HD #2 – present	Stress ulcer prophylaxis	
5. Phenytoin 100 mg via tube	Q8H	HD #2 - present	Seizure	
6. Fluoxetine 20 mg via tube	Daily	HD #1 – present	Depression	
7. NSS infusion	100 mL/hour	HD#7 - present	Hypotension	
8. Norepinephrine infusion	4 mcg/min	HD#7 – present	Hypotension	
9. Promote® with fiber via tube	80 ml/hour continuously	HD#3 – present	Nutrition	
10. Phytonadione 10mg IV	Daily	HD#1 – HD #2	Reversal of anticoagulant state	
11. Phenytoin 1000mg IV	Once	HD#1	Seizure	
Medication History				

Home medications include: Amlodipine 5mg PO daily, Lisinopril 5mg PO daily, Warfarin 2.5 mg daily, and simvastatin as above. Compliance is unknown.

### **ASHP Clinical Skills Competition - Pharmacist's Care Plan**

Evaluated for competition

#### Problem Identification and Prioritization with Pharmacist's Care Plan

Team # \_\_\_\_\_

- A. List all health care problems that need to be addressed in this patient using the table below.
- B. Prioritize the problems by indicating the appropriate number in the "Priority" column below:
  - 1 = Most urgent problem (<u>Note</u>: There can only be <u>one</u> most urgent problem)
  - 2 = Other problems that must be addressed immediately or during this clinical encounter; **OR**
  - 3 = Problems that can be addressed later (e.g. a week or more later)

<sup>\*</sup>Please note, there should be only a "1", "2", or "3" listed in the priority column, and the number "1" should only be used once.

Health Care Problem	Priority	Therapeutic Goals	Recommendations for Therapy	Monitoring Parameters and Endpoints
Hospital-Acquired Pneumonia /Severe Sepsis  Note: students may list sepsis and HAP	1	Resolution of infection Prevention of mortality	Recommend collecting sputum and blood cultures  Cefepime OR ceftazidime OR meropenem OR aztreonam	Monitor for improvement in oxygenation (PaO2 >75) Follow daily WBC/differential – should trend downward Temperature (<100.4F) BP (>90 SBP)
together or separately; if they list separately, the order does not matter – either can be the #1 problem			PLUS  Levofloxacin OR ciprofloxacin  PLUS  Vancomycin to a targeted trough of 15-20 mcg/mL	Cultures – monitor to change to definitive therapy as results return.  No need to perform follow-up respiratory cultures, follow-up blood cultures should be performed if the initial sets are positive
			Treat for 7-8 days unless <i>Pseudomonas</i> is cultured (14-15 days for <i>Pseudomonas</i> ). Though not specifically in the guidelines, <i>Acinetobacter</i> and MRSA can also justify the 14-15 day course of therapy.	May repeat CXR after several days of therapy, but not a required monitoring parameter (patient improvement is enough)
			Doses: Cefepime 2gm IV q24h or 1gm IV	

Health Care Problem	Priority	Therapeutic Goals	Recommendations for Therapy	Monitoring Parameters and Endpoints
			q12h Ceftazidime 1gm IV q12h Meropenem 1gm IV q12h Aztreonam 1-2gm IV q6-8h Levofloxacin 750mg IV q48h Ciprofloxacin 400mg IV q12h Vancomycin dosing is flexible, as long as the target trough of 15-20 mcg/mL is stated AND 1gm q12h is NOT stated.  Incorrect answers: Aminoglycoside (renal toxicity), piperacillin (allergy), imipenem (seizure potential); linezolid (drug interaction)  Note: discontinuing fluoxetine and starting linezolid will not avoid the interaction due to fluoxetine's prolonged half life.	Monitor beta-lactams for hypersensitivity (looking for signs of rash/hives, eosinophils on differential)  FQs: monitor for change in seizure activity  Vancomycin: follow trough concentrations. The frequency of monitoring is variable since the patient is in acute renal failure
Severe Sepsis		Maintain SBP >90 mm Hg MAP > 65 Prevention of mortality/organ damage	Titrate norepinephrine to response Continue NSS infusion Incorrect answer: start activated protein C (contraindication – SAH)	BP Prevention of further organ damage – monitor SCr, LFTs, lactate, urine output
Hyperglycemia (can be combined with sepsis)	2	Blood glucose 80-150 mg/dL Prevention of complications of hyperglycemia (e.g. further infection) Decrease length of stay, ventilator time	Initiate continuous infusion insulin and titrate to response Typical dose: 1.5-2 units/hour	Blood glucose every 1-2 hours Electrolytes daily
Renal failure	2	Avoidance of drugs contraindicated in this disease state	Avoid aminoglycoside use Maintain/increase BP to SBP>90 – give NSS and vasopressor as in sepsis	Follow urine output and serum creatinine, electrolytes

Health Care Problem	Priority	Therapeutic Goals	Recommendations for Therapy	Monitoring Parameters and Endpoints
Seizures	2	Prevention of seizures	A drug-diet interaction exists between phenytoin and tube feedings  1) Either of the below are sufficient:  • Hold tube feeds for 2 hours before and after phenytoin administration  • Change phenytoin to IV (either same dose or 80% of current dose)  2) Students must check a phenytoin concentration. Albumin is 2.8, so either the phenytoin concentration	Free phenytoin concentration 1-2 mcg/mL (or adjusted phenytoin concentration of 10-20 mcg/mL)  Seizure activity  Monitor for nystagnus, other adverse effects of phenytoin as outpatient
			must be adjusted for this by calculation, or a free phenytoin concentration should be checked  Equation for adjusted PHT:  C adj = Creported /(0.2 x serum albumin) + 0.1.  Students do not have the information to calculate this due to the lack of a PHT concentration, but they should consider the role of albumin in the concentration they order (unless it is a free concentration)	
Suboptimal nutrition	2	Improved nutrition; avoidance of further kidney damage, volume overload, and hyperkalemia	Discontinue Promote® with fiber (high volume load)  Begin Nepro® (or TwoCal NH®) at 40 ml/hour continuously (needs to be interrupted for phenytoin if that is still given orally). Rationale: these are calorie-rich products with decreased protein. Students can say "change to	Nutritional status (pre-albumin >15), electrolytes, urine output, glucose

Health Care Problem	Priority	Therapeutic Goals	Recommendations for Therapy	Monitoring Parameters and Endpoints
			calorie-dense tube feeds" instead of brand names.	
Sedation	2	Prevent agitation while on ventilator Sedation score, e.g. Ramsey score = 3 (calm but alert)	Ok to continue propofol or change to intermittent benzodiazepine (i.e. lorazepam 2mg q6h)	Ramsey or other sedation scale Propofol – must check triglycerides q48-72h, should follow BP (SBP>90)
DVT	2	Prevent DVT reformation, PE development	Begin sequential compression devices	DVT: LE swelling, redness, pain PE: pulmonary status, HR
CAD s/p MI	3	Prevention of further CV disease/acute CV event BP <130/80	Begin aspirin 81-162 mg PO q24h when stable (SAH resolved) Restart lisinopril when BP stable Consider initiation of beta-blocker therapy instead of amlodipine when BP stable Continue simvastatin	Bleeding (easy bruising, dark stool, etc)  Potassium, renal function, BP HR  LDL <100 (optional <70) TG <150 HDL >40
Depression	3	Prevention or successful treatment of depression; prevention of suicidal ideation	Continue fluoxetine	Mental health after acute events resolve

<sup>© 2008,</sup> American Society of Health-System Pharmacists®, Inc. All rights reserved.